SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: NNBP - Nanobac Pharmaceuticals Inc. (Bulls Board)

06 Feb 2007 12:18 PM
16 Nov 2006 01:54 PM
02 Nov 2006 08:50 AM
04 Oct 2006 10:56 AM
25 Sep 2006 10:43 AM
19 Sep 2006 05:30 PM
14 Sep 2006 12:14 PM
22 Aug 2006 05:14 PM
28 May 2006 09:50 PM
27 May 2006 10:46 PM <--
23 May 2006 05:30 PM

Return to NNBP - Nanobac Pharmaceuticals Inc. (Bulls Board)
 
Nanobac Pharmaceuticals, Inc. is a broad-based life science company dedicated to the discovery and developments of products and services to improve people’s health through the detection and treatment of Calcifying Nano-Particles, otherwise known as “nanobacteria”. The Company’s pioneering research is establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease.

Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and reagents for the detection of Calcifying Nano-Particles. IVD products include the NANOCAPTURE™ and NANO-SERO™ ELISA assays and the Nano-Vision™ line of antibodies and reagents.Nanobac’s BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials. Nanobac’s Drug Discovery and Development efforts are focused on developing new and existing compounds that effectively inhibit, destroy or neutralize CNPs.

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. Web site nanobac.com.